Alnylam Pharmaceuticals
ALNY
#581
Rank
ยฃ26.82 B
Marketcap
ยฃ207.27
Share price
-0.94%
Change (1 day)
75.11%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.17. In 2022 the company made an earnings per share (EPS) of -ยฃ7.17 a decrease over its 2021 EPS that were of -ยฃ5.56.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-53.95%
2022-ยฃ7.1729.03%
2021-ยฃ5.56-3.36%
2020-ยฃ5.75-8.48%
2019-ยฃ6.287.67%
2018-ยฃ5.8439.74%
2017-ยฃ4.1812.94%
2016-ยฃ3.7038.84%
2015-ยฃ2.66-32.88%
2014-ยฃ3.97259.44%
2013-ยฃ1.10-31.25%
2012-ยฃ1.6152.94%
2011-ยฃ1.0530.77%
2010-ยฃ0.80-8.77%
2009-ยฃ0.8878.13%
2008-ยฃ0.49-70.78%
2007-ยฃ1.6999.09%
2006-ยฃ0.85-43.88%
2005-ยฃ1.51-82.33%
2004-ยฃ8.56-59.23%
2003-ยฃ21.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.31-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ28.84-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.05 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.30-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.89-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.46-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.54-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel